Navigation Links
Avexa's Apricitabine Clinical Trial Update

erial infections. The Company's lead program is apricitabine (ATC) which has recently successfully completed the 21 day dosing of its Phase IIb trial. The Company continues to progress ATC towards Phase III trials. Avexa has entered into a collaboration with TargetDrug in China to identify new CCR5 inhibitors for the treatment of HIV infections and has an exclusive option to licence TargetDrug's lead CCR5 inhibitor, Nifeviroc.

Contact

Avexa
Dr. Julian Chick, +61 3 9208 4300
Chief Executive Officer
www.avexa.com.au
or
Bourse Communications
Mr Rod North, + 61 (03) 9510-8309


'"/>




Page: 1 2

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Avexa Apricitabine Clinical Trial Update
(Date:12/1/2008)...ecember 9 at 11:00 am ET to Discuss Phase 2 Study ... Calif., Dec. 1 Sunesi...armaceutical company focused on the development an...today announced new data from its studies of vorel...nted during the 50th American Society of Hematolog...
(Date:11/28/2008)...ire/ -- German biotech company,Partec is expandin...ing and,AIDS patient follow-up diagnostics for de..., 2.5 million patient tests have been performed wi...Flow" system, supporting already,more than 1 mill...on of the,Partec innovation, the average cost of ...
(Date:11/26/2008)...RANKLIN, Mass., Nov. 26 ...nced today that it has received full approval from...ts U.S. pivotal trial to study the effectiveness o...ted therapy in the prevention of Contrast-Induced ...d PLC,s request to expand their investigation from...
(Date:11/25/2008)...swire-FirstCall/ -- Poniard,Pharmaceuticals, Inc....cused on,innovative oncology therapies, announced...atives for its preclinical research programs in or...n the clinical development of picoplatin,its lea...mmercialization of,picoplatin in the treatment of...
Breaking Medicine Technology:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3German Innovation for HIV/AIDS Diagnostics has Been Used 2.5 Million Times in 2008 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 2Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin 3ExonHit Therapeutics 2007 Financial Results 3736 1ExonHit Therapeutics 2007 Financial Results 3736 2ExonHit Therapeutics 2007 Financial Results 3736 3ExonHit Therapeutics 2007 Financial Results 3736 4ExonHit Therapeutics 2007 Financial Results 3736 5ExonHit Therapeutics 2007 Financial Results 3736 6ExonHit Therapeutics 2007 Financial Results 3736 7ExonHit Therapeutics 2007 Financial Results 3736 8ExonHit Therapeutics 2007 Financial Results 3736 9ExonHit Therapeutics 2007 Financial Results 3736 10ExonHit Therapeutics 2007 Financial Results 3736 11ExonHit Therapeutics 2007 Financial Results 3736 12Quest Diagnostics Named to FORTUNE Magazines Americas Most Admired Companies List 3735 1Quest Diagnostics Named to FORTUNE Magazines Americas Most Admired Companies List 3735 2New Findings Support Alternatives to Pap Test 13540 1New Findings Support Alternatives to Pap Test 13540 2New Findings Support Alternatives to Pap Test 13540 3New Findings Support Alternatives to Pap Test 13540 4AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc for Molecular Quality Control Standards 3734 1AcroMetrix Signs Development and Supply Agreement With Beckman Coulter Inc for Molecular Quality Control Standards 3734 2
(Date:12/2/2008)...RNewswire/ -- MedPro Imaging, a premier provider,...d the appointment of three,new ultrasound sales p...ve,expansion. The company also announced the rel...due to substantial growth throughout 2008. Keith,...nt of Sales and Marketing in,February of this yea...
(Date:12/2/2008)... keep driving safe, research shows , , T... on a cell phone are more distracted and more pron...d sitting next to them in the car, a new report fi...oint attention, so when you have a person sitting ...erson actually understands something about traffic...
(Date:12/2/2008)..., Kessler Foundation continues to improve the live...ST ORANGE, N.J.Dec. 2 One of the l... disabilities, Henry H. Kessler Foundation, announ...oundation. The Foundation is also changing the nam... Research Center and Kessler Foundation Program Ce...
(Date:12/2/2008)...lf Have Skipped Medical Care Due to Cost Issues- ,...swire/ -- A new survey released today by the Natio...hts another troubling aspect of the current financ...care for themselves or their families to save mone...ir health has gotten worse over the past five year...
Breaking Medicine News(10 mins):Health News:MedPro Imaging Continues Aggressive U.S. Expansion 2Health News:Car Cell Phone Use More Hazardous Than Chat With Passengers 2Health News:Car Cell Phone Use More Hazardous Than Chat With Passengers 3Health News:Henry H. Kessler Foundation Rebranded as Kessler Foundation 2Health News:Henry H. Kessler Foundation Rebranded as Kessler Foundation 3Health News:Rising Health Costs Prompt Women to Neglect Health 2Health News:Rising Health Costs Prompt Women to Neglect Health 3Health News:Rising Health Costs Prompt Women to Neglect Health 4
...Carolina at Chapel Hill, in the current issue of P... may be possible molecular origin of at least nine... These neuro degenerative diseases, including Hunt...posit of proteins inside nerve cells. This deposit...
...logged arteries leading to a condition of early at...n the current issue of Psychosomatic Medicine. How...any such tendencies, said the study. The researche...and had found increased thickness of the lining of...
...he journal Antimicrobial Agents and Chemotherapy p...s that occur in the human saliva can lead to new w...y in children. Researchers at the University of Wa...ne a possible correlation between dental caries (t...
...l death for elderly people. A new study conducted ...s are four times more likely to fall than those wh...e are estimated to have type 2 diabetes, and the n... people by 2025. Previous investigations have def...
Other Medicine News:
Herpes Simplex Virus 2 IgG ELISA.
Cytomegalovirus IgM ELISA.
Small Incision Microforceps: Tano ILM Forceps
Blunt tipped forceps with a thin tip angled at approximately 135 and hollowed out "notch" on the interior of the distal end. Tip is shaped like a pic when in the closed position. For membrane peeling
Medicine Products: